Estrella Immunopharma Valuation
| ESLAW Stock | 0.09 0.00 0.00% |
Estrella Immunopharma seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Estrella Immunopharma from reviewing the firm fundamentals such as EBITDA of (7.31 M), total debt of 180.7 K, and Beta of -0.09 as well as analyzing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Estrella Immunopharma's price fluctuation is out of control at this time. Calculation of the real value of Estrella Immunopharma is based on 3 months time horizon. Increasing Estrella Immunopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Estrella stock is determined by what a typical buyer is willing to pay for full or partial control of Estrella Immunopharma. Since Estrella Immunopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Estrella Stock. However, Estrella Immunopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.091 | Real 0.0797 | Hype 0.0794 | Naive 0.1 |
The intrinsic value of Estrella Immunopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Estrella Immunopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Estrella Immunopharma helps investors to forecast how Estrella stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Estrella Immunopharma more accurately as focusing exclusively on Estrella Immunopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Estrella Immunopharma's intrinsic value based on its ongoing forecasts of Estrella Immunopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Estrella Immunopharma's closest peers.
Estrella Immunopharma Cash |
|
Estrella Valuation Trend
Analysing the historical paterns of Estrella Immunopharma's enterprise value and its market capitalization is a good way to estimate and gauge the value of Estrella Immunopharma over time and is usually enough for investors to make rational market timing decisions.
Estrella Immunopharma Total Value Analysis
Estrella Immunopharma is currently forecasted to have takeover price of 0 with market capitalization of 0, debt of 180.7 K, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Estrella Immunopharma fundamentals before making investing decisions based on enterprise value of the companyEstrella Immunopharma Asset Utilization
One of the ways to look at asset utilization of Estrella is to check how much profit was generated for every dollar of assets it reports. Estrella Immunopharma shows a negative utilization of assets of -1.75 percent, losing USD0.0175 for each dollar of assets held by the firm. Inadequate asset utilization denotes the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Estrella Immunopharma shows how discouraging it operates for each dollar spent on its assets.Estrella Immunopharma Profitability Analysis
Net Loss for the year was (7.31 M) with profit before overhead, payroll, taxes, and interest of 0.About Estrella Immunopharma Valuation
Our relative valuation model uses a comparative analysis of Estrella Immunopharma. We calculate exposure to Estrella Immunopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Estrella Immunopharma's related companies.Estrella Immunopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Estrella Immunopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 35.2 M |
Estrella Immunopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Estrella Immunopharma and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Estrella we look at many different elements of the entity such as Estrella's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Estrella Immunopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Estrella Immunopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Estrella Immunopharma's worth.Additional Tools for Estrella Stock Analysis
When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.